Side-by-side · Research reference

MOTS-cvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/68 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly doseLee 2015

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

MOTS-c

Vesugen

Primary target

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Not applicable — does not operate via hormone axis

Origin

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

MOTS-c

Vesugen

Standard dose

5–10 mg / weekLee 2015

Experimental, extrapolated from animal data. No human RCT-derived dose.

—

Frequency

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Not specified in available literature

Lower / starter dose

2.5–5 mg / week

Recommended due to limited human data.

—

Evidence basis

Animal + anecdotalLee 2015 Reynolds 2021 A first-in-human phase 1 study 2021

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

4–12 weeks (experimental)

Optimal cycle length unknown.

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

—

Timing

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

—

Half-life

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

03Metabolic / Fat Loss Evidence

Parameter

MOTS-c

Vesugen

Primary fat target

Diet-induced / metabolic obesity; systemic fat utilization

—

Quantified reduction

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

—

IGF-1 impact

No direct IGF-1 pathway; AMPK-mediated

—

Effect on lean mass

High dose significantly ↑ lean mass in mice

—

Insulin sensitivity

Reversed HFD insulin resistance in 7 days (mice)Lee 2015

—

Triglycerides

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

—

Glucose metabolism

Improved glucose tolerance; GLUT4 upregulationLee 2015

—

Effect reversibility

Unknown — no long-term follow-up data

—

Context dependency

No effect in normal-chow mice; requires metabolic stressReynolds 2021

—

Key publication

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015 Reynolds 2021 Kim 2018

—

04Side Effects & Safety

Parameter

MOTS-c

Vesugen

Injection site reaction

Mild irritation (reported)

—

Fluid retention / Edema

Not reported

—

Glucose intolerance

Improves glucose toleranceLee 2015

—

Cardiovascular

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

—

Cancer risk

Contradictory data — some models suggest pro-proliferative effects

—

CNS / Neurological

Insomnia, headache (anecdotal reports)

—

GI symptoms

Nausea, stomach discomfort (reported)

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

—

Evidence quality

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Vesugen

—

Relative Contraindications

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

MOTS-c

Vesugen

1. Reconstitution

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

—

06Stack Synergy

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)